Generics - Zydus Cadila, Diabetes

Filter

Current filters:

Zydus CadilaDiabetes

Popular Filters

1 to 25 of 1645 results

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

16-04-2014

UK pharma giant GlaxoSmithKline yesterday received the much anticipated approval from the US Food and…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationTanzeumUSA

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

Depomed settlements with two Gralise ANDA filers

15-04-2014

US specialty drugmaker Depomed has entered into settlement agreements with two of the three defendants…

DepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsUSAZydus Cadila

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

Indian govt plans to support a competitive pharma sector, especially for SMEs

Indian govt plans to support a competitive pharma sector, especially for SMEs

14-04-2014

In a bid to strengthen the existing infrastructure facilities and to enable the Indian pharmaceutical…

Asia-PacificGenericsIndiaMarkets & MarketingPoliticsProduction

Despite focus on generics, South Korean pharma market to reach $24.3 billion by 2020

Despite focus on generics, South Korean pharma market to reach $24.3 billion by 2020

10-04-2014

As a result of a high level of access to health care insurance and reimbursement, coupled with increasing…

Asia-PacificGenericsMarkets & MarketingPolitics

EGA president seeks partnership with Italian government on generics and biosimilars

09-04-2014

The president of the European Generic Medicines Association (EGA), Nick Haggar, attended the Stati Generali…

BiosimilarsEuropeGenericsItalyMarkets & MarketingPolitics

Teva launches first generic Lovaza in USA

Teva launches first generic Lovaza in USA

08-04-2014

Israel-based Teva Pharmaceutical Industries says it has received US Food and Drug Administration approval…

Cardio-vascularGenericsGlaxoSmithKlineLovazaMarkets & MarketingRegulationTeva Pharmaceutical IndustriesUSA

US/EU generic industries call for thoughtful changes to speed medicines to patients

US/EU generic industries call for thoughtful changes to speed medicines to patients

08-04-2014

In a joint letter sent to the European Commission and the Office of the US Trade Representative, the…

EuropeGenericsPoliticsRegulationUSA

Takeda ordered to pay $6 billion damages in Actos trial

Takeda ordered to pay $6 billion damages in Actos trial

08-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical has been ordered to pay $6 billion in punitive damages…

ActosDiabetesEli Lilly and CompanyJapanJudgeLegalMajorPharmaceuticalPyridinesTakeda NycomedThiazolidinedionesUSA

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

07-04-2014

In something of a surprise announcement, Sun Pharmaceutical Industries revealed this morning that it…

Daiichi SankyoGenericsIndiaMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Sweden’s Meda rejects Mylan’s takeover overture

Sweden’s Meda rejects Mylan’s takeover overture

06-04-2014

After a day of rumor and speculation about a takeover approach from US generic firm Mylan, Swedish drugmaker…

GenericsMedaMergers & AcquisitionsMylan Laboratories

Actavis opens new Asia Pacific regional headquarters in Singapore

03-04-2014

Ireland-headquartered generics major Actavis has officially opened its new regional office in Singapore…

ActavisAsia-PacificGenericsManagementMarkets & Marketing

Pamplona buys majority stake in US generic firm Alvogen

02-04-2014

Pamplona Capital Management has as acquired a majority stake in privately-held US company Alvogen, which…

AlvogenGenericsMergers & Acquisitions

Hikma’s US facility back in compliance

Hikma’s US facility back in compliance

02-04-2014

Hikma Pharmaceuticals, Jordan's largest pharmaceutical company, has received a close-out letter from…

GenericsHikma PharmaceuticalsJordanPharmaceuticalRegulation

European generic drug makers sets out priorities for EU Trade Policy

European generic drug makers sets out priorities for EU Trade Policy

02-04-2014

European Generic Medicines Association (EGA) revealed this morning that its president, Nick Haggar, has…

EuropeGenericsPoliticsRegulationRest of the World

MannKind’s diabetes drug Afrezza recommended by FDA advisory

02-04-2014

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AfrezzaDiabetesMannKindNorth AmericaPharmaceuticalRegulationUSA

Actavis forks out $100 million for Thai generics firm

Actavis forks out $100 million for Thai generics firm

02-04-2014

Ireland-headquartered US generic major Actavis has acquired Silom Medical Company, a privately held generic…

Asia-PacificAurobindo PharmaGenericsMergers & AcquisitionsSilom Medical CompanyTeva Pharmaceutical Industries

Prasco to market the authorized generic of Lilly’s Evista in USA

01-04-2014

Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly to market…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsMarkets & MarketingNorth AmericaPrasco LaboratoriesUSA

1 to 25 of 1645 results

Company Spotlight

Fibrotech

Fibrotech

Back to top